Braveheart Bio Management
Management criteria checks 1/4
Braveheart Bio's CEO is Travis Murdoch, appointed in Jul 2025, has a tenure of 1.08 years. total yearly compensation is $486.12K, comprised of 33.1% salary and 66.9% bonuses, including company stock and options. directly owns 12.99% of the company’s shares, worth $250.01M. The average tenure of the management team and the board of directors is 0.7 years and 0.9 years respectively.
Key information
Travis Murdoch
Chief executive officer
US$486.1k
Total compensation
| CEO salary percentage | 33.12% |
| CEO tenure | 1.1yrs |
| CEO ownership | 13.0% |
| Management average tenure | less than a year |
| Board average tenure | less than a year |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$80m |
| Dec 31 2025 | US$486k | US$161k | -US$66m |
Compensation vs Market: Travis's total compensation ($USD486.12K) is below average for companies of similar size in the US market ($USD5.13M).
Compensation vs Earnings: Insufficient data to compare Travis's compensation with company performance.
CEO
Travis Murdoch (41 yo)
Dr. Travis Murdoch, M.D., M.Sc. & B.S., has been Chief Executive Officer of Braveheart Bio, Inc. since July 2025, President since October 2025 and its director since September 2025. He is Director of Ollin...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 1.1yrs | US$486.12k | 12.99% $ 250.0m | |
| Chief Financial Officer | less than a year | US$1.76m | 1.1% $ 21.1m | |
| Chief Development Officer | less than a year | US$475.01k | 0.52% $ 10.0m | |
| Chief Scientific Officer | less than a year | no data | no data | |
| VP & Head of Legal | less than a year | no data | no data | |
| Director of Corporate Development | no data | no data | no data | |
| Associate Director of Human Resources & Office Manager | no data | no data | no data | |
| Senior Vice President of Development Operations | less than a year | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data | |
| Chief Business Officer | less than a year | no data | no data | |
| Senior Vice President of Cardiovascular Research & Translational Science | no data | no data | no data | |
| Senior Vice President of Chemistry | no data | no data | no data |
Experienced Management: BRVE's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$486.12k | 12.99% $ 250.0m | |
| Independent Director | less than a year | no data | 0.087% $ 1.7m | |
| Independent Chairman | less than a year | US$33.83k | 1.05% $ 20.3m | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Director | 2.3yrs | US$51.65k | 1.58% $ 30.4m | |
| Board Observer | no data | no data | no data | |
| Director | less than a year | no data | no data | |
| Board Observer | no data | no data | no data | |
| Independent Director | less than a year | no data | no data |
Experienced Board: BRVE's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/09 23:03 |
| End of Day Share Price | 2026/08/07 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Braveheart Bio, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.